Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBITDA Margin for 3 consecutive years, with 2106.85% as the latest value for Q2 2025.

  • Quarterly EBITDA Margin rose 15879115.0% to 2106.85% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 9721.02% through Dec 2025, up 554135.0% year-over-year, with the annual reading at 10386.54% for FY2025, 15533746.0% up from the prior year.
  • EBITDA Margin for Q2 2025 was 2106.85% at Inhibrx Biosciences, down from 1595.43% in the prior quarter.
  • The five-year high for EBITDA Margin was 1595.43% in Q1 2025, with the low at 160898.0% in Q2 2024.
  • Average EBITDA Margin over 3 years is 49017.42%, with a median of 21956.66% recorded in 2023.
  • The sharpest move saw EBITDA Margin crashed -4452476bps in 2024, then skyrocketed 15879115bps in 2025.
  • Over 3 years, EBITDA Margin stood at 5403.24% in 2023, then plummeted by -824bps to 49928.0% in 2024, then surged by 96bps to 2106.85% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 2106.85%, 1595.43%, and 49928.0% for Q2 2025, Q1 2025, and Q4 2024 respectively.